Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, B-Cell 5Burkitt Lymphoma 5Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Biphenotypic, Acute 1

Interventions

Cytarabine 13Cyclophosphamide 11fludarabine 10Filgrastim 8fludarabine phosphate 7Methotrexate 7Vincristine 6Specimen Handling 5Dexamethasone 5Biopsy 5venetoclax 4revumenib 4Granulocyte Colony-Stimulating Factor 4Doxorubicin 4Azacitidine 4Whole-Body Irradiation 3Prednisone 3Mycophenolic Acid 3Leucovorin 3Hydrocortisone 3Clofarabine 3selinexor 2merphos 2ixazomib 2blinatumomab 2aldesleukin 2X-Rays 2Vorinostat 2Topotecan 2Thiotepa 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Biphenotypic, Acute × Inotuzumab Ozogamicin × Clear all
NCT01925131 2023-05-03

S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia

SWOG Cancer Research Network

Phase 1 Completed
50 enrolled 14 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡